These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 32707672)

  • 1. Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment.
    Miyazaki T; Ishikawa E; Sugii N; Matsuda M
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32707672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
    Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
    J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.
    Cui X; Ma C; Vasudevaraja V; Serrano J; Tong J; Peng Y; Delorenzo M; Shen G; Frenster J; Morales RT; Qian W; Tsirigos A; Chi AS; Jain R; Kurz SC; Sulman EP; Placantonakis DG; Snuderl M; Chen W
    Elife; 2020 Sep; 9():. PubMed ID: 32909947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
    Simonds EF; Lu ED; Badillo O; Karimi S; Liu EV; Tamaki W; Rancan C; Downey KM; Stultz J; Sinha M; McHenry LK; Nasholm NM; Chuntova P; Sundström A; Genoud V; Shahani SA; Wang LD; Brown CE; Walker PR; Swartling FJ; Fong L; Okada H; Weiss WA; Hellström M
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting FGL2 in glioma immunosuppression and malignant progression.
    Ma X; Zhu H; Cheng L; Chen X; Shu K; Zhang S
    Front Oncol; 2022; 12():1004700. PubMed ID: 36313679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy: a promising approach for glioma treatment.
    Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
    Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
    Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
    Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications.
    Himes BT; Geiger PA; Ayasoufi K; Bhargav AG; Brown DA; Parney IF
    Front Oncol; 2021; 11():770561. PubMed ID: 34778089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
    Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
    Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions.
    Ser MH; Webb MJ; Sener U; Campian JL
    J Immunother Precis Oncol; 2024 May; 7(2):97-110. PubMed ID: 38721406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for glioblastoma: current state, challenges, and future perspectives.
    Liu Y; Zhou F; Ali H; Lathia JD; Chen P
    Cell Mol Immunol; 2024 Dec; 21(12):1354-1375. PubMed ID: 39406966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
    Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
    Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
    Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
    Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
    Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
    J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma.
    Chen Q; Han B; Meng X; Duan C; Yang C; Wu Z; Magafurov D; Zhao S; Safin S; Jiang C; Cai J
    Int J Cancer; 2019 Jul; 145(2):517-530. PubMed ID: 30613962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.